Are MDCX insiders buying or selling?

In the last 90 days, Medicus Pharma (MDCX) had 13 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own MDCX?

See every hedge fund and asset manager holding Medicus Pharma (MDCX).

How much of MDCX trades in dark pools?

Track Medicus Pharma (MDCX) dark pool activity and off-exchange block trades.

Medicus Pharma (MDCX) — 50.7% Short — Squeeze Watch

$0.28

-0.04 (-12.01%)

Weekly Expected Move ±16.0%

$0 $0 $0 $0 $0

NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 27 · $6.2M mcap · 4M float · 47.35% daily turnover · Short 43% of daily vol

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions ETF Exposure Dark Pool Short Interest

Smart Money Score

Watch 25

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$6.2M

52W Range0.25-3.05

Volume2,017,135

Avg Volume2,064,038

Beta-0.65

Dividend—

Analyst Ratings

2 Buy 0 Hold 0 Sell

Consensus Buy

Company Info

CEORaza Bokhari

Employees16

SectorHealthcare

IndustryBiotechnology

IPO Date2024-11-15

Websitemedicuspharma.com

300 Conshohocken State Rd. Suite 200
W. Conshohocken 19428
CA

+1 416 861 1685

About Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.

Latest News

Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome

Bullish GlobeNewsWire-FDA · 1d ago

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

Bullish GlobeNewsWire-FDA · 1w ago

12 Health Care Stocks Moving In Thursday's Intraday Session

Bullish Benzinga-Movers · 5w ago

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

Bullish GlobeNewsWire-FDA · 6w ago

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

Bullish GlobeNewsWire-FDA · 7w ago

Recent Insider Trades

Name	Type	Shares	Price	Date
Mehmud Faisal	A-Award	250,000	$0.36	2026-06-03
May Sara R.	A-Award	50,000	$0.36	2026-06-03
MAHAFFY PATRICK J	A-Award	50,000	$0.36	2026-06-03
Kaiser Larry	A-Award	50,000	$0.36	2026-06-03
FISHMAN BARRY	A-Award	50,000	$0.36	2026-06-03

MDCX NASDAQ

Recent Insider Trades

Sign in to InsiderStreet